A Phase 1b/2, Multicenter,Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Eribulin (Primary) ; Capecitabine
- Indications Advanced breast cancer; Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 10 Aug 2016 Status changed from active, no longer recruiting to completed.
- 06 May 2016 Planned number of patients changed from 116 to 76.
- 06 May 2016 Planned End Date changed from 1 May 2014 to 1 Jun 2016.